A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)
Phase of Trial: Phase III
Latest Information Update: 16 Aug 2018
At a glance
- Drugs Pneumococcal vaccine (Primary) ; V 114 (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate
- Indications Pneumococcal infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Acronyms PNEU-PATH
- Sponsors Merck Sharp & Dohme
- 29 Jun 2018 Status changed from not yet recruiting to recruiting.
- 16 May 2018 Planned End Date changed from 29 Oct 2019 to 5 Dec 2019.
- 16 May 2018 Planned primary completion date changed from 29 Oct 2019 to 5 Dec 2019.